Business

BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

Highly statistically significant improvements in PEC score observed vs. placebo

articleBioxcel Therapeutics, Inc.July 20, 20205/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-primary-and-secondary-endpoints-met-in-two-pivotal-phase-3-trials-of-bxcl501-for-the-acute-treatment-of-agitation-in-patients-with-schizophrenia-and-bipolar-disorder

BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

About this update from Bioxcel Therapeutics, Inc.

[{"type":"text","content":"Highly statistically significant improvements in PEC score observed vs. placebo (p","length":104,"tagName":"div"}]

More updates from Bioxcel Therapeutics, Inc.